Advertisement

Innovations in the Psychopharmacologic Treatment of Schizophrenia

  • John M. Kane

Abstract

The treatment of schizophrenia represents a major challenge to clinicians. The role of pharmacologic and somatic treatments in this disorder is an important one; however, clinicians must appreciate both the complexity and the potential heterogeneity of the disorder in order to provide optimal management within a particular modality.

Keywords

Antipsychotic Drug Schizophrenic Patient Antipsychotic Medication Tardive Dyskinesia Extrapyramidal Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angrist, B., Pesselow, E., Rubenstein, M., Wolkin, A., & Rotrosen, J. (1985). Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology, 85, 277–283.PubMedCrossRefGoogle Scholar
  2. Angrist, B., Rotrosen, J., & Gershon, S. L. (1980). Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology, 67, 31–38.PubMedCrossRefGoogle Scholar
  3. Baldessarini, R., Katz, B., & Cotton, P. (1984). Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry, 141, 748–752.PubMedGoogle Scholar
  4. Bergling, R., Mjorndal, T., Oreland, L., Rapp, W., & Wold, S. (1975). Plasma levels and clinical effects of thioridazine and thiothixene. Journal of Clinical Pharmacology, 15, 178–186.PubMedCrossRefGoogle Scholar
  5. Bjorndal, N., Bjerre, M., Gerlach, J., Kristjansen, P., Magelund, G., Oestrich, I. H., & Wachrems, J. (1980). High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol and serum prolac-tin. Psychopharmcology, 67, 17–23.CrossRefGoogle Scholar
  6. Bleuler, M. (1978). The schizophrenic disorder: Long-term patients and family studies (S. M. Clemens, Trans.). New Haven: Yale University Press.Google Scholar
  7. Bolvig-Hansen, L. B., Larsen, N. E., & Vestergaard, P. (1981). Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology, 74, 306–309.CrossRefGoogle Scholar
  8. Brandon, S., Cowley, P., McDonald, C., Neville, P., Palmer, R., Wellstood-Eason, S., & Leicester, R. (1985). ECT trial: Results in schizophrenia. British journal of Psychiatry, 146, 177–183.PubMedCrossRefGoogle Scholar
  9. Caffey, E. M., Jr., Diamond, L. S., Frank, T. V., Grasberger, J. C., Herman, L., Klett, C. J., & Rothstein, C. (1964). Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases, 17, 347–358.PubMedCrossRefGoogle Scholar
  10. Carpenter, W. T., & Heinrichs, D. W. (1984). Intermittent pharmacotherapy of schizophrenia. In J. Kane (Ed.), Drug maintenance strategies in schizophrenia (pp. 69–82). Washington, DC: American Psychiatric Press.Google Scholar
  11. Carpenter, W. T., Stephens, J. H., Rey, A. C., Hanlon, T. E., & Heinrichs, D. W. (1982). Early intervention vs. continued pharmacotherapy of schizophrenia. Psychopharmacology Bulletin, 18, 21–23.Google Scholar
  12. Casper, R., Garver, D. L., Dekirmenjian, H., Chang, S., & Davis, J. M. (1980). Phenothiazine levels in plasma and red blood cells: Their relationship to clinical improvement in schizophrenia. Archives of General Psychiatry, 37, 301–305.PubMedCrossRefGoogle Scholar
  13. Cheung, H. K. (1981). Schizophrenics fully remitted on neuroleptics for 3-5 years: To stop or continue drugs? British Journal of Psychiatry, 138, 490–494.PubMedCrossRefGoogle Scholar
  14. Chien, C. P. (1975). Drugs and rehabilitation in schizophrenia. In M. Greenblatt (Ed.), Drugs in combination with other therapies (pp. 13–34). New York: Grune & Stratton.Google Scholar
  15. Chouinard, G., & Jones, B. (1980). Neuroleptic induced supersensitivity psychosis: Clinical and pharmacologic characteristics. American Journal of Psychiatry, 137, 16–21.PubMedGoogle Scholar
  16. Ciompi, L. (1980a). Three lectures on schizophrenia: The natural history of schizophrenia in the long-term. British Journal of Psychiatry, 136, 413–420.PubMedCrossRefGoogle Scholar
  17. Ciompi, L. (1980b). Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin, 6, 606–618.PubMedCrossRefGoogle Scholar
  18. Claghorn, J., Honigfeld, G., Abuzzahab, F. S., Wang, R., Steinbook, R., Tuason, V., & Klerman, G. (1987). The risks and benefits of clozapine vs. chlorpromazine. Journal of Clinical Psychopharmacology, 7, 377–384.PubMedCrossRefGoogle Scholar
  19. Cohen, B. M., Lipinski, J. F., Harris, P. O., Pope, H. G., & Friedman, M. (1980). Clinical use of the radioreceptor assay for neuroleptics. Psychiatry Research, 2, 173–178.PubMedCrossRefGoogle Scholar
  20. Cohen, B. M., Lipinski, J. F., Pope, H. G., Harris, P. O., & Altesman, R. I. (1980). Neuroleptic blood level and therapeutic effect. Psychopharmocology, 70, 191–193.CrossRefGoogle Scholar
  21. Crawford, R., & Forrest, A. (1974). Control trial of depot fluphenazine in outpatient schizophrenics. British Journal of Psychiatry, 124, 385–391.PubMedCrossRefGoogle Scholar
  22. Crow, T. J., McMillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986). The Northwick Park study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120–127.PubMedCrossRefGoogle Scholar
  23. Davis, J. M. (1975). Overview: Maintenance therapy in psychiatry—I. Schizophrenia. American Journal of Psychiatry, 132, 1237–1245.PubMedGoogle Scholar
  24. Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980). Important issues in the drug treatment of schizophrenia. Schizophrenia Bulletin, 6, 70–87.PubMedCrossRefGoogle Scholar
  25. Delva, N. J., & Letemendia, F. J. J. (1982). Lithium treatment in schizophrenia and schizo-affective disorders. British Journal of Psychiatry, 141, 387–400.PubMedCrossRefGoogle Scholar
  26. Dencker, S. J., Lepp, M, & Malm, U. (1980). Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatrica Scan-dinavica (Suppl.), 279, 64–76.Google Scholar
  27. Dysken, M. W., Javaid, J. I., Chang, S. S., Schaffer, C., Shaid, A., & Davis, J. M. (1981). Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology, 73, 205–210.PubMedCrossRefGoogle Scholar
  28. Engelhardt, D. M., Freedman, M., Rosen, B., Mann, D., & Margolis, R. (1964). Phe-nothiazines in the prevention of psychiatric hospitalization: III. Delay or prevention of hospitalization. Archives of General Psychiatry, 11, 162–169.PubMedCrossRefGoogle Scholar
  29. Engelhardt, D. M., Rosen, B., Freedman, N., Mann, D., & Margolis, R. (1963). Phe-nothiazines in the prevention of psychiatric hospitalization: II Duration of treatment exposure. Journal of the American Medical Association, 186, 981–983.PubMedCrossRefGoogle Scholar
  30. Engelhardt, D. M., Rosen, B., Freedman, N., & Margolis, R. (1967). Phenothiazines in prevention of psychiatric hospitalization: IV. Delay or prevention of hospitalization—A reevaluation. Archives of General Psychiatry, 16, 98–101.PubMedCrossRefGoogle Scholar
  31. Falloon, I. R. H., Watts, D. C., & Shepherd, M. (1978). A comparative controlled trial of pimozide and fluphenazine decanoate in continuation therapy of schizophrenia. Psychological Medicine, 8, 59–70.PubMedCrossRefGoogle Scholar
  32. Garver, D. L., Dekirmenjian, H., Davis, J. M., Casper, R., & Ericksen, S. (1977). Neuroleptic drug levels and therapeutic response: Preliminary observations with red blood cell bound butaperazine. American Journal of Psychiatry, 134, 304–307.PubMedGoogle Scholar
  33. Garver, D. L., Hirschowitz, J., Glicksteen, G. A., Kanter, D. R., & Mavroidis, M. L. (1984). Haloperidol plasma and red blood cell levels and clinical antipsychotic response. Journal of Psychopharmacology, 4, 133–137.Google Scholar
  34. Gerlach, J., Koppelhus, E., Helweg, E., & Monrad, A. (1974). Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatrica Scandinavica, 50, 410–424.PubMedCrossRefGoogle Scholar
  35. Goldstein, M. J., Rodnick, E. H., Evans, J. R., May, P. R. A., & Steinberg, M. R. (1978). Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry, 35, 1169–1177.PubMedCrossRefGoogle Scholar
  36. Haase, H. J. (1961). Extrapyramidal modification of fine movements—A “conditio sine qua non” of the fundamental therapeutic action of neuroleptic drugs. In J. M. Bordeleau (Ed.), Extrapyramidal system and neuroleptics (pp. 329–353). Montreal: Montreal Editions Psychiatriques.Google Scholar
  37. Haase, H. J., & Janssen, A. P. J. (1965). The action of neuroleptic drugs. Chicago: Yearbook Medical Publishers.Google Scholar
  38. Harding, C. M., Brooks, G. W., Askihaga, T., Strauss, J. S., & Breier, A. (1987). The Vermont longitudinal study: II. Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry, 144, 727–735.PubMedGoogle Scholar
  39. Herz, M. I., & Melville, C. (1980). Relapse in schizophrenia. American Journal of Psychiatry, 137, 801–805.PubMedGoogle Scholar
  40. Herz, M. I., Szymanski, H. B., & Simon, J. C. (1982). Intermittent medication for stable schizophrenic outpatients: An alternative to maintenance medication. American Journal of Psychiatry, 139, 918–922.PubMedGoogle Scholar
  41. Hirsch, S. R., Gaind, R., Rohde, P. D., Stevens, B. C., & Wing, J. K. (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial. British Medical Journal, 1, 633–637.PubMedCrossRefGoogle Scholar
  42. Hirschowitz, J., Casper, R., Garver, D. L., & Chang, S. (1980). Lithium response in good prognosis schizophrenia. American Journal of Psychiatry, 137, 916–920.PubMedGoogle Scholar
  43. Hogarty, G. E., Goldberg, S. C., & the Collaborative Study Group. (1974). Drug and so-ciotherapy in the aftercare of schizophrenic patients: One year relapse rates. Archives of General Psychiatry, 28, 54–64.CrossRefGoogle Scholar
  44. Hogarty, G. E., Goldberg, S. C., Schooler, N. R., Ulrich, R. F., & the Collaborative Study Group. (1979). Drug and sociotherapy in the aftercare of schizophrenic patients: II. Two year relapse rate. Archives of General Psychiatry, 31, 603–608.CrossRefGoogle Scholar
  45. Hogarty, G. E., Schooler, N. R., Ulrich, R. F., Mussare, F., Ferro, P., & Herron, E. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydro-chloride. Archives of General Psychiatry, 36, 1283–1294.PubMedCrossRefGoogle Scholar
  46. Hogarty, G. E., Ulrich, R. F., Mussare, F., & Aristigueta, N. (1976). Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Diseases of the Nervous System, 37, 494–500.PubMedGoogle Scholar
  47. Honigfeld, G., Patin, J., & Singer, J. (1984). Antipsychotic activity in treatment resistance schizophrenics. Advances in Therapy, 1, 77–97.Google Scholar
  48. Huber, G., Gross, G., & Schüttler, R. (1979). Verlaufs-und Sozialpsychiatriche langzeitunter-suchunder an den 1945-1959 in Benn Hospitalizierten Schizophren Kranken Monogr. Gesantgeb Psychiatr. (Berline). English Abstract, 21, 1–3999.Google Scholar
  49. Huber, G., Gross, G., Schüttler, R., & Linz, M. (1980). Longitudinal studies of schizophrenic patients. Schizophrenia Bulletin, 6, 592–605.PubMedCrossRefGoogle Scholar
  50. Itil, T. M., Keskiner, A., Heinemann, L., Han, T., Gannen, P., & Hsu, W. (1970). Treatment of resistant schizophrenics with extreme high dosage fluphenazine hydrochloride. Psychoso-matics, 11, 456–463.Google Scholar
  51. Janowsky, D. S., & Davis, J. M. (1976). Methylphenidate, dextroamphetamine and levam-fetamine: Effects on schizophrenic symptoms. Archives of General Psychiatry, 33, 304–308.PubMedCrossRefGoogle Scholar
  52. Janowsky, D. S., El-Yousef, K., Davis, J. M., & Sekerke, J. (1973). Provocations of schizophrenic symptoms by intravenous administration of methylphenidate. Archives of General Psychiatry, 28, 185–191.PubMedCrossRefGoogle Scholar
  53. Johnson, D. A. W. (1976). The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica, 53, 298–301.PubMedCrossRefGoogle Scholar
  54. Johnson, D. A. W. (1979). Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry, 135, 524–530.PubMedCrossRefGoogle Scholar
  55. Kane, J. M., & Borenstein, M. (1985). Compliance in the long-term treatment of schizophrenia. Psychopharmacology Bulletin, 21, 23–27.PubMedGoogle Scholar
  56. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistance schizophrenic: A double-blind comparison versus chlorpromazine/benztropine. Archives of General Psychiatry, 45, 789–796.PubMedCrossRefGoogle Scholar
  57. Kane, J. M., & Lieberman, J. A. (1987). Maintenance pharmacotherapy in schizophrenia. In H. Y. Meltzer (Ed.), Psychopharmacology, the third generation of progress: The emergency of molecular biology and biological psychiatry (pp. 1103–1109). New York: Raven Press.Google Scholar
  58. Kane, J. M., Rifkin, A., Quitkin, F., Nayak, D. V., & Ramos-Lorenzi, J. R. (1982). Fluphenazine versus placebo in patients with remitted, acute first episodes of schizophrenia. Archives of General Psychiatry, 39, 70–73.PubMedCrossRefGoogle Scholar
  59. Kane, J. M., Rifkin, A., Woerner, M., Reardon, G., Kreisman, L., Blumenthal, R., & Borenstein, M. (1985). High-dose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacology Bulletin, 21, 533–537.PubMedGoogle Scholar
  60. Kane, J. M., Rifkin, A., Woerner, M., Reardon, G., Sarantakos, S., Schiebel, D., & Ramos-Lorenzi, J. R. (1983). Low dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry, 40, 893–896.PubMedCrossRefGoogle Scholar
  61. Kane, J. M., Rifkin, A., Woerner, M., & Sarantakos, S. (1986). Dose response relationships in maintenance drug treatment for schizophrenia. Psychopharmacology Bulletin, 6, 205–235.Google Scholar
  62. Kane, J. M., Woerner, M., Borenstein, M., Wegner, J., & Lieberman, J. (1986). Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin, 22, 254–258.PubMedGoogle Scholar
  63. Kelly, H. B., Freeman, H. L., Banning, B., & Schiff, A. (1977). A clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. International Pharmacopsychology, 12, 54–64.Google Scholar
  64. Leff, J. P., & Wing, J. K. (1971). Trial of maintenance therapy in schizophrenia. British Medical Journal, 3, 559–605.CrossRefGoogle Scholar
  65. Lieberman, J., Kane, J., Sarantakos, S., Gadaleta, D., & Woerner, M. (1987). Prediction of relapse in schizophrenia. Archives of General Psychiatry, 44, 597–603.PubMedCrossRefGoogle Scholar
  66. Magliozzi, J. R., Hollister, L. E., Arnold, K. V., & Earlie, G. M. (1981). Relationship of serum haloperidol levels to clinical response in schizophrenic patients. American Journal of Psychiatry, 138, 365–367.PubMedGoogle Scholar
  67. Marder, S. R., Van Putten, T., Mintz, J., Lebelle, M., Faltico, G., & May, P. R. A. (1984). Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry, 41, 1025–1029.PubMedCrossRefGoogle Scholar
  68. Marder, S. R., Van Putten, T., Mintz, J., Lebelle, M., McKenzie, J., & May, P. R. A. (1987). Low and conventional dose maintenance therapy with fluphenazine decanoate: Two year outcome. Archives of General Psychiatry, 44, 518–521.PubMedCrossRefGoogle Scholar
  69. Mavroidis, M. L., Kanter, D. R., Hirschowitz, J., & Garver, D. L. (1983). Clinical response and plasma in haloperidol levels in schizophrenia. Psychopharmacology, 81, 354–356.PubMedCrossRefGoogle Scholar
  70. Mavroidis, M. L., Kanter, D. R., Hirschowitz, J., & Garver, D. L. (1984). Therapeutic blood levels of fluphenazine: Plasma or RBC determinations? Psychopharmacology Bulletin, 20, 168–170.PubMedGoogle Scholar
  71. May, P. R. A. (1968). Treatment of schizophrenia: A Comparative study of five treatment methods. New York: Science House.Google Scholar
  72. May, P. R. A., Van Putten, T., Jenden, D. J., Yale, C., & Dixon, W. j. (1981). Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Archives of General Psychiatry, 38, 202–207.PubMedCrossRefGoogle Scholar
  73. McCreadie, R. G., Dingwall, J. M., Wiles, D. H., & Heykants, J. J. P. (1980). Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry, 137, 510–517.PubMedCrossRefGoogle Scholar
  74. McCreadie, R. G., Mackie, M., Morrison, D., & Kidd, J. (1982). Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry, 140, 280–286.PubMedCrossRefGoogle Scholar
  75. McCreadie, R. G., & McDonald, I. M. (1977). High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry, 131, 210–316.CrossRefGoogle Scholar
  76. McEvoy, J., Stiller, R. L., & Farr, R. (1986). Plasma haloperidol levels drawn on neuroleptic threshold doses: A pilot study. Journal of Clinical Psychopharmacology, 6, 133–138.PubMedCrossRefGoogle Scholar
  77. Neborsky, R. J., Janowsky, D. S., Perel, J. M., Munson, E., & Depry, D. (1984). Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry, 45, 10–13.PubMedGoogle Scholar
  78. Odejide, O. A., & Aderounmu, A. F. (1982). Double-blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry, 43, 195–196.PubMedGoogle Scholar
  79. Potkin, S. G., Shen, Y., Zhou, D., Pardes, H., Shu, L., Phelps, B., & Poland, R. (1985). Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychophar-macology Bulletin, 21, 59–61.Google Scholar
  80. Quitkin, F., Rifkin, A., Kane, J. M., Ramos-Lorenzi, J. R., & Klein, D. F. (1978). Long-acting oral versus injectable antipsychotic drugs in schizophrenics: A one-year double-blind comparison in multiple episode schizophrenics. Archives of General Psychiatry, 35, 889–892.PubMedCrossRefGoogle Scholar
  81. Quitkin, F., Rifkin, A., & Klein, D. F. (1975). Very high dosage versus standard dosage fluphenazine in schizophrenia: A double-blind study of non-chronic treatment refractory patients. Archives of General Psychiatry, 32, 1276–1281.PubMedCrossRefGoogle Scholar
  82. Rifkin, A., Quitkin, F., Rabiner, C. J., & Klein, D. F. (1977). Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. Archives of General Psychiatry, 34, 43–47.PubMedCrossRefGoogle Scholar
  83. Salzman, C. (1980). The use of ECT in the treatment of schizophrenia. American Journal of Psychiatry, 137, 1032–1041.PubMedGoogle Scholar
  84. Schooler, N. R., & Keith, S. J. (1983). Treatment strategies in schizophrenia study protocol. Rockville, MD: National Institute of Mental Health.Google Scholar
  85. Schooler, N. R., Levine, J., Severe, J. B., Brauzer, B., DiMascio, A., Klerman, G. L., & Tauson, V. B. (1980). Prevention of relapse in schizophrenia: An evaluation of fluphenazine decanoate. Archives of General Psychiatry, 37, 16–24.PubMedCrossRefGoogle Scholar
  86. Small, J. G., Kellams, J. J., Millstein, V., & Moore, J. (1975). A placebo controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry, 132, 1315–1317.PubMedGoogle Scholar
  87. Smith, R. C., Baumgartner, R., Ravichandran, G. K., Shvartsburd, A., Schooler, J. C., Allen, P., & Johnson, R. (1984). Plasma and cell levels of thioridazine and clinical response in schizophrenia. Psychiatry Research, 12, 287–296.PubMedCrossRefGoogle Scholar
  88. Smith, R. C., Baumgartner, R., Shvartsburd, A., Ravichandran, G. K., Vroulis, G., & Mauldin, M. (1985). Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Psychopharmacology, 85, 449–455.PubMedCrossRefGoogle Scholar
  89. Taylor, P. J., & Fleminger, J. J. (1980). ECT for schizophrenia. Lancet, 1, 1380–1382.PubMedCrossRefGoogle Scholar
  90. Troshinsky, C. H., Aaronson, H. G., & Stone, R. K. (1962). Maintenance phenothiazine in the aftercare of schizophrenic patients. Pennsylvania Psychiatric Quarterly, 2, 11–15.Google Scholar
  91. Van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67–72.PubMedCrossRefGoogle Scholar
  92. Van Putten, T., Marder, S. R., May, P. R. A., Poland, R. E., & O’Brien, R. (1985). Plasma levels of haloperidol and clinical response. Psychopharmacology Bulletin, 21, 69–72.PubMedGoogle Scholar
  93. Wistedt, B. (1981). A depot neuroleptic withdrawal study: A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthioxol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandinavica, 64, 65–84.PubMedCrossRefGoogle Scholar
  94. Wode-Helgodt, B., Borg, S., Fyro, B., & Sedvall, G. (1978). Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatrica Scandinavica, 58, 149–173.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • John M. Kane
    • 1
  1. 1.Department of PsychiatryHillside Hospital, Division of Long Island Jewish Medical CenterGlen OaksUSA

Personalised recommendations